title: Effectiveness of the immunofecal occult blood test for colorectal cancer screening in a large population.
abstract: BACKGROUND
  Guaiac tests are the most widely used tests to detect colorectal cancer (CRC). However, their sensitivity is relatively low and results may be affected by various factors. Immunofecal occult blood test (IFOBT) is specific for human hemoglobin and does not require dietary restrictions.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the effectiveness of IFOBT for the screening of precancerous lesions and CRC.
  
  
  METHODS
  From July 2006 to June 2007, IFOBT was performed on 5,919 adults who received periodic health examinations in our hospital. The positive cases were examined by colonoscopy and a double-contrast barium enema. Diagnosis was confirmed by histopathological analysis.
  
  
  RESULTS
  Positive IFOBT was detected in 314 of 5,919 cases (5.30%). Further examinations were made in 264 IFOBT-positive cases. Of these, 116 cases with colorectal cancer (16 cases) or precancerous lesions (94 cases with colorectal adenomatous polyps and 6 cases with active ulcerative colitis) were detected. The total detection rate of CRC and precancerous lesions was 43.94% (116/264). TNM classification of 16 CRC cases was as follows: TNM I in eight cases (50.00%), TNM II in seven cases (43.75%) and TNM III in one case (6.25%), indicating IFOBT can detect CRC in the early stages.
  
  
  CONCLUSIONS
  Regular IFOBT can detect precancerous lesions and CRC in early stages and can thus reduce mortality from CRC.
authors.affiliation: Department of Gastroenterology, Renji Hospital, Shanghai Institute of Digestive Disease, Shanghai Jiao Tong University School of Medicine, Shanghai, 200001, China.
authors.forename: Haiyun
authors.initials: H
authors.lastname: Yang
authors.forename: Zhizheng
authors.initials: Z
authors.lastname: Ge
authors.forename: Jun
authors.initials: J
authors.lastname: Dai
authors.forename: Xiaobo
authors.initials: X
authors.lastname: Li
authors.forename: Yunjie
authors.initials: Y
authors.lastname: Gao
mesh_terms: D018256:Adenomatous Polyps / Q000175:diagnosis / Q000453:epidemiology; D000328:Adult; D000368:Aged; D002681:China / Q000453:epidemiology; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000453:epidemiology; D055088:Early Detection of Cancer / Q000379:methods*; D005243:Feces; D005260:Female; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged; D009780:Occult Blood; D011230:Precancerous Conditions / Q000175:diagnosis / Q000453:epidemiology; D012189:Retrospective Studies; D012680:Sensitivity and Specificity
references.citation: Lancet. 1996 Nov 30;348(9040):1467-71
references.pmid: 8942774
references.citation: Am J Gastroenterol. 2005 Jun;100(6):1393-403
references.pmid: 15929776
references.citation: Am J Gastroenterol. 2009 Jan;104(1):149-53
references.pmid: 19098863
references.citation: Ann Oncol. 2002 Jan;13(1):57-60
references.pmid: 11863112
references.citation: Prev Med. 1994 May;23(3):309-13
references.pmid: 8078851
references.citation: J Med Screen. 2002;9(3):99-103
references.pmid: 12370319
references.citation: Am J Gastroenterol. 2005 Nov;100(11):2519-25
references.pmid: 16279909
references.citation: J Natl Cancer Inst. 1997 Oct 1;89(19):1406-22
references.pmid: 9326910
references.citation: Gut. 2003 Mar;52(3):321-2
references.pmid: 12584209
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):654-7
references.pmid: 15066933
references.citation: Ann Oncol. 2002 Jan;13(1):31-4
references.pmid: 11863106
references.citation: Ann Oncol. 2005;16 Suppl 2:ii127-32
references.pmid: 15958442
references.citation: J Clin Gastroenterol. 2006 Nov-Dec;40(10):913-8
references.pmid: 17063111
references.citation: N Engl J Med. 1993 May 13;328(19):1365-71
references.pmid: 8474513
references.citation: J Natl Cancer Inst. 2005 Aug 3;97(15):1107-9
references.pmid: 16077063
references.citation: Ann Oncol. 2002 Jan;13(1):47-50
references.pmid: 11863110
references.citation: Am Fam Physician. 2002 Dec 15;66(12):2287-90
references.pmid: 12507168
references.citation: N Engl J Med. 1992 Mar 5;326(10):658-62
references.pmid: 1736104
references.citation: Ann Oncol. 2002 Jan;13(1):51-6
references.pmid: 11863111
references.citation: Eur J Cancer Prev. 2004 Feb;13(1):71-5
references.pmid: 15075791
references.citation: CA Cancer J Clin. 2006 Jan-Feb;56(1):11-25; quiz 49-50
references.pmid: 16449183
references.citation: J Natl Cancer Inst. 2002 Aug 7;94(15):1126-33
references.pmid: 12165637
references.citation: Ann Oncol. 2002 Jan;13(1):44-6
references.pmid: 11863109
references.citation: CA Cancer J Clin. 2003 Jan-Feb;53(1):44-55
references.pmid: 12568443
references.citation: Aliment Pharmacol Ther. 2006 May 1;23(9):1359-64
references.pmid: 16629942
references.citation: Lancet. 1996 Nov 30;348(9040):1472-7
references.pmid: 8942775